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Introduction
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) most often presents 
with dyspnea and a nonproductive cough. The progression and prognosis of the 
disease are usually determined by the ILD subtype. The most common subtype is 
usual interstitial pneumonia (UIP) followed by non-specific interstitial pneumonia (NSIP).1 
For most, the disease remains sub-clinical without progression. Flares can occur,  
being precipitated by insult to the lungs including infection and even lung biopsy.2 
Case presentation
A 44-year-old female with a history of non-erosive rheumatoid arthritis on 
methotrexate, IV drug abuse, and slowly progressive ILD presented to the hospital 
due to hypoxemia and worsening cough. Computed tomography (CT) of the chest 
demonstrated interlobular septal thickening, subpleural peripheral honeycombing and 
ground-glass opacities with a bibasilar and posterior predominance (Images 1 and 
2). Methotrexate was discontinued and the patient was started on broad spectrum 
antibiotics with initiation of an infectious workup. Due to her unclear etiology of lung 
disease and failure to improve on antibiotics, a video assisted right upper lung biopsy 
on day six of hospitalization was performed. The pathology showed fibrosis with 
honeycombing and dilatation of bronchi consistent with UIP. The patient was then 
started on pulse dose steroids and rituximab as her hypoxia worsened. Eleven days 
after biopsy the patient was emergently intubated and ultimately placed on veno-
venous extracorporeal membrane oxygenation (VV-ECMO) for refractory hypoxemia. 
Her course was complicated by streptococcal bacteremia with septic shock, 
Pseudomonas ventilator associated pneumonia, superior vena cava thrombus, and 
severe oropharyngeal bleeding. Unfortunately, the patient was not a candidate for 
lung transplant due to her severity of illness and multiple infections. She was 
ultimately taken off of life support on day 68 of hospitalization. 
Discussion
•  Acute respiratory failure of unclear etiology can be difficult to treat as 
management can vary drastically. The differential diagnosis in this case 
includes methotrexate toxicity, infection, and RA-ILD. 
•  Ultimately the patient was diagnosed with a flare of her ILD with surgical 
lung biopsy possibly further exacerbating the flare. 
•  Biopsy may have been avoided with her CT findings being consistent 
with UIP pattern. One could argue that pathology would likely show 
similar findings and not be contributory to changing the course of 
treatment. 
•  Regardless of the cause, RA-ILD flares can be difficult to manage as 
treatment with steroids may not be enough and rituximab can take up to 
4-6 weeks before seeing clinical improvement, if at all.
Conclusion
RA-ILD can atypically progress at a rapid rate. When considering open 
lung biopsy, it is judicious to weigh the risks versus the benefits involved. 
For patients with already progressive ILD, flares must be considered as 
one of those risks.
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Imaging
Image 1. CT chest in the transverse view 
showing interlobular septal thickening, 
subpleural peripheral honeycombing and 
ground-glass opacities.
Image 2. Sagittal view of left lung showing 
subpleural peripheral disease with a basilar 
and posterior predominance.  
